Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next EU COVID-19 Vaccine Contracts Will Take On ‘Lessons Learned’ In Capacity And Supply

EMA OKs Boost In Production Capacity For Pfizer/BioNTech & Moderna

Executive Summary

The European Commission appears to be favoring mRNA vaccines in its negotiations with companies on the next generation of COVID-19 vaccine contracts. Manufacturing finally appears to be gaining momentum, and the health commissioner claims the EU has “turned the corner” with its vaccination programs.

You may also be interested in...



Coronavirus Notebook: EU Launches Vaccine Monitoring Scheme, AZ Vows To Defend Itself Against Legal Action

The EMA has issued updated safety advice on AstraZeneca’s COVID-19 vaccine, Vaxzevria, Valneva has decided to pursue vaccine supply deals with individual member states after a falling out with the European Commission, and Kazakhstan has begun administering the first doses of its domestically produced vaccine, QazVac.

AZ And J&J’s Problems Fuel Demand For Pfizer and Moderna COVID-19 Vaccines

Pfizer/BioNTech is emerging as the EU’s partner of choice for COVID-19 vaccines, but others could also benefit.

Novavax Plays Down EU COVID Vaccine Contract Delay

Investors are anxious about the delay to Novavax’s deal with the EU, and want to know how and when it might file the vaccine with regulators.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel